Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function

https://doi.org/10.20996/1819-6446-2020-04-06

Full Text:

Abstract

Comorbid patients with atrial fibrillation, diabetes mellitus and chronic kidney disease are at high risk of stroke. The direct oral anticoagulants are indicated for them. The choice of a drug should be based on the results of randomized clinical trials, in which the patients profile corresponds to that in the real Russian clinical practice as much as possible. Taking into account the peculiarities of comorbidity in this category of patients, the requirements for their protection should be considered comprehensively. Along with the prevention of thromboembolic complications, it is necessary that the selected direct oral anticoagulant provides a reduction in the risk of cardiovascular complications, which are typical of diabetes mellitus, and slows down the progression of renal filtration function decline. Rivaroxaban may meet these requirements; its use has significant advantage in high adherence to therapy.

About the Authors

N. V. Drobotya
Rostov State Medical University
Russian Federation

Natalia V. Drobotya – MD, PhD, Professor, Head of Chair of Cardiology, Rheumatology and Functional Diagnostics

Nakhichevansky per. 29, Rostov-on-Don, 344022



E. Sh. Guseynova
Rostov State Medical University
Russian Federation

Elvira Sh. Guseynova – MD, PhD, Assistant, Chair of Cardiology, Rheumatology and Functional Diagnostics

Nakhichevansky per. 29, Rostov-on-Don, 344022



A. A. Pirozhenko
Rostov State Medical University
Russian Federation

Anna A. Pirozhenko – MD, PhD, Associate Professor, Chair of Therapy

Nakhichevansky per. 29, Rostov-on-Don, 344022



References

1. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. DOI:10.1093/eurheartj/ehw210.

2. Movahed M.R., Hashemzadeh M., Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to over cardiovascular disease. Int J Cardiol. 2005;105:315-8. DOI:10.1016/j.ijcard.2005.02.050

3. Ehrlich A.D. Atrial fibrillation combine d with diabetes mellitus. Possibilities of using Rivaroxaban. Aterotromboz. 2018;2:68-74 (In Russ.) DOI:10.21518/2307-1109-2018-2-68-74.

4. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-23. DOI:10.1161/CIRCULATIONAHA.106.679597.

5. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387-97. DOI:10.1161/CIRCULATIONAHA.106.634949.

6. Wild S., Roglic G., Green A. et al. Global prevalence of diabetes: estimates for year 2000 and projections for 2030. Diabetes Care 2004;21:1047-53. DOI:10.2337/diacare.27.5.1047.

7. Kanorsky S.G., Kanorskaya Yu.S. Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Specific Features of Development and Antirecurrence Therapy. Kardiologiya. 2010;7:31-7 (In Russ.)

8. Dedov I.I., Shestakova M.V., eds. Diabetes mellitus: diagnosis, treatment, prevention. Moscow: Medical news Agency; 2011 (In Russ.)

9. Shestakova М.V. Diabetes mellitus and chronic kidney disease: modern diagnostics and treatment. Vestnik RAMN. 2012;1:45-9 (In Russ.)

10. Reutens A.T. Epidemiology of diabetic kidney disease. Med Clin N Am. 2013;97(1):1-18. DOI:10.1016/j.mcna.2012.10.001.

11. Eikelboom J.W., Weitz J.I. New anticoagulants. Circulation. 2010;121(13):1523-32. DOI:10.1161/CIRCULATIONAHA.109.853119.

12. Patel M.R., Mahaffey K.W., Garg J., et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.

13. Connolly S.J., Ezekowitz M.D., Yusuf S., et al., the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.

14. Lopes R.D., Alexander J.H., Al-Khatib S.M., et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9. DOI:10.1016/j.ahj.2009.07.035.

15. Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27:6:238-47. DOI:10.1161/ATVBAHA.107.139402.

16. Friberg L., Skeppholm M., Terént A. Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. Journal of the American college of Cardiology 2015;65(3):225-232. DOI:10.1016/j.jacc.2014.10.052.

17. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. DOI:10.1093/eurheartj/ehr342.

18. Granger Ch. B., Alexander J.H., John J.V. McMurray et.al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. NEJM. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.

19. Napalkov D.A., Sokolova A.A. Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy. Rational Pharmacotherapy in Cardiology. 2019;15(4):553-7 (In Russ.) DOI:10.20996/1819-6446-2019-15-4-553-557.

20. Shulman V.A. Evidence-based medicine. How much proof is it? Sibirskoye Medicinskoye Obozreniye. 2007;43(2):92-6 (In Russ.)

21. Kirchhof P., Radaideh D.M., Young-Hoon Kim M.D., et al. Global Safety Analysis of Rivaroxaban: A Pooled Analysis of the Global Prospective, Observational XANTUS Program. J Am Coll Cardiol. 2018;72(2):141-53. DOI:10.1016/j.jacc.2018.04.058.

22. Spencer F.A., Moscucci M., Granger C.B., et al. for the GRACE Investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116:2793-801. DOI:10.1161/CIRCULATIONAHA.107.694273.

23. Subherwal S., Bach R.G., Chen A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of unstable angina patients Suppress Adverse outcomes with early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119:1873-82. DOI:10.1161/CIRCULATIONAHA.108.828541.

24. Olesen J. B., Lip G. Y. H., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-35. DOI:10.1056/NEJMoa1105594.

25. Kropacheva E.S. Practical Aspects of Therapy with New Oral Anticoagulants in Patients With Impaired Renal Function. Kardiologiia. 2014;2:78-83 (In Russ.)

26. Daabul I.S., Sokolova A.A., Napalkov D.A. Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Rational Pharmacotherapy in Cardiology. 2016;12(5):595-602 (In Russ.) DOI:10.20996/1819-6446-2016-12-5-595-602.

27. Gu H.F., Brismar K. Genetic association studies in diabetic nephropathy. Curr. Diabet. Rev. 2012;8(5):336-44. DOI:10.2174/157339912802083522.

28. Arora M.K., Singh U.K. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vasc Pharmacol. 2013;58(4):259-71. DOI:10.1016/j.vph.2013.01.001.

29. Mukhin N.A., Glybochko P.V., Svistunov A.A., et al. Chronic kidney disease and atrial fibrillation as components of the cardiorenal continuum. Ter Arkhiv. 2016;6:4-8 (In Russ.)

30. Yao X., Tangri N., Gersh B., et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017;70(21):2621-32. DOI:10.1016/j.jacc.2017.09.1087.

31. Fatemi O., Yuriditsky E., Tsioufis C. et al. Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (from the ACCORD Study). The American Journal of Cardiology. 2014;114(8):1217-22. DOI:10.1016/j.amjcard.2014.07.045.

32. Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2:e001592. DOI:10.1136/bmjopen-2012-001592


For citation:


Drobotya N.V., Guseynova E.S., Pirozhenko A.A. Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function. Rational Pharmacotherapy in Cardiology. 2020;16(2):296-300. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-06

Views: 98


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)